The objective of this review is to identify the effect of the involvement of significant others in chronic pain management programs for adult patients with chronic non-malignant pain on function, self-efficacy and pain.More specifically, the objectives are to identify the effect of involving significant others in chronic management programs for adults with chronic non-malignant pain in primary, secondary or tertiary health care. This is compared to those receiving usual care or other self-management interventions.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.11124/JBISRIR-2016-003239 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Everolimus with or without mycophenolate mofetil for GVHD prophylaxis after allogeneic HSCT in children with acute kidney injury - a single-center retrospective analysis.
Transplant Cell Ther
January 2025
Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt - Universität zu Berlin, and Berlin Institute of Health, Department of Pediatric Oncology and Hematology, Berlin, Germany; German Cancer Consortium (DKTK), Heidelberg, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany; Department of Hematology and Oncology, University Children's Hospital, Eberhard Karls University Tuebingen, Tuebingen, Germany.
Background: Hematopoietic stem cell transplantation (HSCT) serves as a therapeutic intervention for various pediatric diseases. Acute and chronic graft-versus-host disease (GVHD) are decisive determinants for allogeneic HSCT success. The immunosuppressive agent, ciclosporin A, is most often used to prevent GVHD in pediatric patients, but is known to be nephrotoxic.
View Article and Find Full Text PDFMixed T-Cell Chimerism Following Hematopoietic Cell Transplantation for Non-Malignant Disorders Is Common, Facilitates Anti-Viral Immunity, and Is Not Associated with Graft Failure in Pediatric Patients.
Cells
December 2024
Departments of Blood and Marrow Transplant, Royal Manchester Children's Hospital, Manchester M13 9WL, UK.
Myeloid chimerism better reflects donor stem cell engraftment than whole-blood chimerism in assessing graft function following allogeneic hematopoietic stem cell transplant (HCT). We describe our experience with 130 patients aged younger than 18 years, treated with allogeneic HCT using bone marrow or PBSC from HLA-matched donors for non-malignant diseases, whose pre-transplant conditioning therapy included alemtuzumab and who were monitored with lineage-specific chimerism after transplant. At 6 years post-transplant, overall survival (OS) was 91.
View Article and Find Full Text PDFDiagnostic and Therapeutic Aspects of Monoclonal Gammopathies of Renal Significance (MGRS): An Update.
Diagnostics (Basel)
December 2024
Unit of Clinical Pathology, Department of Medical and Surgical Sciences, University of Foggia, University Hospital "Policlinico Riuniti", Viale Luigi Pinto, 71122 Foggia, Italy.
Monoclonal gammopathy of renal significance (MGRS) refers to a group of renal disorders caused by a monoclonal immunoglobulin (MIg), secreted by a non-malignant B-cell clone. Unlike overt multiple myeloma or B-cell proliferation, MGRS does not meet those diagnostic criteria. However, it is associated with significant morbidity, due to severe renal, and sometimes systemic, lesions induced by the MIg.
View Article and Find Full Text PDFArticle Synopsis
- Allogeneic haematopoietic stem cell transplantation (alloHSCT) shows high survival rates (90% overall survival) in adolescents and adults with severe inborn errors of immunity (IEI), as assessed in a study of 82 patients.
- The study found that pre-transplant immune dysregulation (measured by the IDDA v2.1 score) and the haematopoietic cell transplantation comorbidity index (HCT-CI) score significantly affected transplant outcomes, including overall survival and event-free survival.
- Notably, a portion of patients with a high IDDA v2.1 score and low HCT-CI score indicates that existing risk assessments may underestimate the risks of alloHSCT, highlighting
CAR T-cell therapy for systemic lupus erythematosus: current status and future perspectives.
Front Immunol
January 2025
Innovation & Research Department, OriCell Therapeutics Co. Ltd., Shanghai, China.
Article Synopsis
- Systemic lupus erythematosus (SLE) and lupus nephritis (LN) are autoimmune disorders that lead to chronic inflammation and organ damage, with current treatments lacking a definitive cure.
- Recent studies suggest that chimeric antigen receptor T-cell (CAR-T) therapy, which has been effective in B-cell cancers, may also be a breakthrough treatment for SLE.
- This paper analyzes CAR-T therapy's mechanisms, clinical data on its efficacy in targeting B-cells for SLE treatment, and emphasizes the need for further research in improving therapeutic strategies for these complex conditions.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!